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Introduction
Variation in DNA methylation has been associated with pre-
disposition, progression and response to treatment of a broad 
range of clinical conditions such as cancer and autoimmune 
diseases.1 Due to its chemical stability, cytosine methylation 
(5mC) in the CpG dinucleotide context can be reliably detected 
from many different sources such as body fluids (e.g., blood and 
urine), buccal mucosa, as well as fresh and archived tissues.2
Technological advances in next-generation sequencing have 
enabled studies of DNA methylation variation on a genome-wide 
scale and with single CpG resolution. Such methods include 
whole-genome bisulfite sequencing (WGBS), reduced repre-
sentation bisulfite sequencing (RRBS) and methylCRF, which 
combines methylated DNA immunoprecipitation (MeDIP-seq) 
and methylation-sensitive restriction enzyme sequencing (MRE-
seq). However, these techniques are still prohibitively costly, 
resource-intensive and inefficient when assessing large numbers 
of samples.2-4
Microarray-based applications, foremost the Illumina 
Infinium HumanMethylation450 BeadChip (“450K array”), 
interrogate only a predefined fraction of the DNA methylome 
but at reduced cost.5 Indeed, 450K arrays have proven to be 
the method of choice for epigenome-wide association studies 
(EWAS), in which disease-associated DNA methylation variable 
positions are identified in case-control sample cohorts.6,7 Several 
techniques have been established to map DNA methylation with 
single CpG resolution at a selected subset of genomic regions 
of interest (e.g., to validate EWAS signals), including pyrose-
quencing, Sanger sequencing and high-resolution melting curve 
analysis. However, most of these have not been optimized for 
high-throughput applications.8,9
Emerging techniques that utilize next-generation DNA 
sequencing platforms are particularly promising for the large-
scale, targeted bisulfite sequencing of genomic regions of interest. 
For example, the enrichment of selected bisulfite-converted loci 
has been achieved by array-based10 and solution-based11 hybrid-
ization capture as well as bisulfite padlock probes,12-14 combined 
with next-generation sequencing of the captured loci. Recently, 
RainDance Technologies developed an alternative and fully inte-
grated enrichment system using microdroplet PCR that can also 
be coupled to next-generation sequencing platforms.15 The encap-
sulation of distinct PCR reactions in microdroplets enables the 
sensitive, specific and simultaneous amplification of up to 20 000 
and 4000 target loci using unconverted and bisulfite-converted 
genomic DNA, respectively. Its application for targeted bisulfite 
sequencing was first reported in 2011 by Komori et al.16 to ana-
lyze over 77 000 CpGs in primary human CD4+ T cells, and 
Herrmann et al.17 to track hepitype evolution in tumors. In 2013, 
Guilhamon et al. refined the method into RainDrop BS-seq and 
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We present a systematic assessment of rainDrop BS-seq, a novel method for large-scale, targeted bisulfite sequenc-
ing using microdroplet-based pCr amplification coupled with next-generation sequencing. We compared DNA meth-
ylation levels at 498 target loci (1001 pCr amplicons) in human whole blood, osteosarcoma cells and an archived tumor 
tissue sample. We assessed the ability of rainDrop BS-seq to accurately measure DNA methylation over a range of DNA 
quantities (from 10 to 1500 ng), both with and without whole-genome amplification (WGA) following bisulfite conver-
sion. DNA methylation profiles generated using at least 100 ng correlated well (median R = 0.92) with those generated 
on illumina infinium HumanMethylation450 BeadChips, currently the platform of choice for epigenome-wide association 
studies (EWAS). WGA allowed for testing of samples with a starting DNA amount of 10 and 50 ng, although a reduced cor-
relation was observed (median R = 0.79). We conclude that rainDrop BS-seq is suitable for measuring DNA methylation 
levels using nanogram quantities of DNA, and can be used to study candidate epigenetic biomarker loci in an accurate 
and high-throughput manner, paving the way for its application to routine clinical diagnostics.
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used it to validate a hypermethylation phenotype in isocitrate 
dehydrogenase (IDH) mutant chondrosarcoma.18
The key limitation of RainDrop BS-seq is the requirement 
of large quantities of DNA as starting material (i.e., 4 μg before 
bisulfite conversion), impeding its application to clinical samples 
such as tumor fragments obtained by laser capture microdis-
section, fluorescence-sorted or stem cell populations, for which 
often only nanogram quantities of DNA are available. To this 
end, Bundo et al. recently evaluated the reproducibility of mul-
tiple displacement amplification (MDA)-based whole-genome 
amplification (WGA) of bisulfite-treated DNA compared with 
unamplified samples. The results indicated reasonable correla-
tion between amplified and unamplified DNA methylation pro-
files, i.e., R
s
 = 0.86 and R
s
 = 0.93 for 10 and 50 ng, respectively.19 
While this assessment concerned methylation profiles generated 
on 450K arrays, it showed the potential benefit of applying WGA 
to samples of limited DNA quantity.
Here, we present a systematic assessment of RainDrop BS-seq 
as a method for large-scale, targeted bisulfite sequencing using 
a wide range of starting DNA quantity and quality, different 
cell types and application of MDA-based WGA of bisulfite-
converted DNA. In addition, we correlate the DNA methylation 
profiles generated with those obtained on 450K arrays to validate 
RainDrop BS-seq as a suitable method for EWAS validation and 
replication experiments.
Results and Discussion
Sample preparation
We isolated human genomic DNA from whole blood, the 
osteosarcoma cell line 143B, and a formalin-fixed paraffin-
embedded (FFPE) tumor sample (Methods section). We applied 
bisulfite conversion to 1500, 1000, 250, and 100 ng of genomic 
DNA from each sample. In parallel, we bisulfite-treated and sub-
sequently applied MDA-based WGA to another 250, 100, 50, 
and 10 ng of genomic DNA from each sample.
Primer panel design
We designed two independent primer panels to measure 
methylation levels at selected genomic regions. Each interrogated 
target locus was centered on at least one specific CpG site that 
is also present on the 450K array platform. First, we targeted 27 
loci (500 PCR amplicons) containing a total of 212 CpG sites 
that are represented on the 450K array (Table S1A). These loci 
were recently identified as being differentially methylated in 
central chondrosarcoma with and without IDH mutations.18 
The sarcoma panel (“SC panel”) was used with eight different 
starting DNA amounts from each of whole blood (BL), osteo-
sarcoma cells (SCL) and an FFPE sample (see above). Second, 
we targeted an additional 462 candidate epigenetic biomarker 
loci (501 PCR amplicons) containing 778 of the 450K CpG sites 
(Table S1B). These loci were selected as part of an ongoing epi-
genetic biomarker validation experiment (Bock et al., in prepara-
tion). Here, the biomarker panel (“BM panel”) was applied to BL 
and SCL samples only. Both primer panels were devised using 
a primer design algorithm described in detail by Komori et al.16 
The primer design pipeline utilizes the Primer3 software as well 
as electronic PCR to restrict off-target amplification. All steps 
of the primer panel generation were performed by RainDance 
Technologies.
RainDrop BS-seq
Bisulfite-treated DNA was used as template for the micro-
droplet-based PCR amplification reaction with a RainDance 
ThunderStorm system (Fig. 1). After destabilization of the 
microdroplet PCR, the purified PCR amplicons were ana-
lyzed on an Agilent 2100 Bioanalyzer. Samples that did not 
undergo WGA (“unamplified samples”) demonstrated a DNA 
Figure  1. rainDrop BS-seq workflow. rainDrop BS-seq allows targeted, high-throughput bisulfite sequencing using the microdroplet-based pCr 
amplification system developed by rainDance technologies. the custom primer panel for the genomic regions of choice is prepared by rainDance 
technologies. the workflow comprises the following key steps: (1) bisulfite conversion of genomic templates; (2) merger of picoliter-volume droplets 
of bisulfite-treated templates with pre-made primer pair droplets (primer panel) on microfluidic chips; (3) pooled, thermal cycling of the pCr reactions 
(microdroplet pCr); (4) destabilization of droplets to release the pCr products; (5) purification of pCr products using magnetic beads; (6) incorpora-
tion of DNA sequencing barcodes through standard pCr (universal pCr), followed by purification of the pCr products and illumina sequencing. the 
workflow comprises a two-step tailed primer strategy. first, target sequences (A) are amplified with tailed primers containing a partial illumina adapter 
sequence (B). Second, the remainder of the illumina adapter sequence as well as a unique barcode sequence (C) is added to enable multiplexing of 
samples for next-generation DNA sequencing.
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quantity-dependent enrichment at the expected fragment size 
range (Fig. S1A–E). While WGA samples also showed enrich-
ment at the expected size range, additional unspecific, high-
molecular artifacts were observed (Fig. S1A–E). The latter may 
have arisen through incomplete bisulfite conversion, after which 
high-molecular DNA fragments get preferably amplified in 
MDA-based WGA.20 However, such high-molecular fragments 
are unlikely to serve as templates for the microdroplet PCR due 
to steric hindrance within the droplets, and thus do not carry the 
incorporated sequence tag crucial for the subsequent PCR step 
(Fig. 1). The amplified PCR fragments then served as templates 
for a second (“universal”) PCR step to incorporate the sequencing 
adapters and unique barcodes to enable Illumina DNA sequenc-
ing. Following purification, PCR products were again analyzed 
on an Agilent 2100 Bioanalyzer. Both unamplified and WGA 
samples demonstrated successful integration of Illumina adapters 
(Fig. S2A–E). The samples were combined in equimolar concen-
trations, and the library sequenced on an Illumina MiSeq.
Targeted DNA sequencing statistics
We analyzed the sequencing data as described in the Methods 
section, with sequencing statistics shown in Table S2A and B. 
For the SC panel (Table S2A), the fraction of aligned sequenc-
ing reads mapping to the target amplicons ranged between 
93.0–97.4% for unamplified BL and SCL samples. For unam-
plified FFPE samples, the fraction ranged between 81.4–84.5%. 
Taken together, this suggests a relatively small impact of starting 
DNA amount (between 100–1500 ng) on read mapping speci-
ficity. WGA did not improve the target coverage in comparison 
to unamplified samples of the same quantity of DNA material, 
i.e., 100 and 250 ng (Table S2A and B). Samples with a starting 
DNA amount of 10 and 50 ng attained a target coverage of at 
least 59.8%. Note that samples with DNA quantities of 10 and 
50 ng were only processed following WGA. Target coverage pro-
files obtained for the BM panel followed a similar read coverage 
pattern as for the SC panel (Table S2B).
Figure 2 gives an overview of the average read coverage per 
individual PCR amplicon for the two primer panels. Notably, 
only one PCR amplicon across the two panels failed to amplify 
in any of the samples tested. For the BM panel, only the samples 
with a starting material of 10 and 50 ng had a PCR amplification 
success rate of less than 95% (Fig. 2A). For the SC panel, this 
was also the case for the 10 ng samples in BL, and 10 and 50 ng 
samples in FFPE (Fig. 2B). In summary, these results indicate a 
robust performance overall of the custom primer panel applied 
to different tissue types and DNA quantities, however it is less 
reliable when applied to WGA-treated DNA.
Next, we assessed the fraction of target bases with a coverage 
ranging from 1 to 1000 across the 462 and 27 target loci of the BM 
(Fig. 3A and B) and SC panel (Fig. S3A–C), respectively. Across 
both primer panels, and in line with the data shown in Figure 2, 
Figure 2. Average per-base sequencing read coverage across pCr amplicons. the heatmaps show the average per-base read coverage across the ~500 
pCr amplicons using the (A) BM primer panel and (B) SC panel. the color scheme indicates different levels of read coverage, i.e., 0, 1, 5 and 10. pCr 
amplicons were mostly covered with at least five sequencing reads across all samples other than those with a starting DNA material of 10 and 50 ng.
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the 10 and 50 ng WGA samples showed markedly reduced cover-
age levels compared with all other samples. In order to assess the 
effect of different starting DNA quantities on target coverage, 
we calculated the standard deviation between samples at differ-
ing coverage levels. For the BM panel, with a 5-fold coverage the 
standard deviation of coverage values across unamplified BL and 
SCL samples was σ = 0.013 and σ = 0.036, respectively, suggest-
ing little effect of input quantity. In contrast, the standard devia-
tion was σ = 0.185 and σ = 0.289, respectively, with a coverage of 
100 sequencing reads (Fig. 3A and B). We confirmed this trend 
using the SC panel, although smaller standard deviation values 
were observed with a coverage of 100 sequencing reads (Fig. S3A 
and B). This was likely due to the increased tiling (i.e., multi-
ple, overlapping PCR amplicons) at the target loci. These results 
indicate a negligible effect of different starting DNA amounts of 
unamplified samples on the fraction of target bases with a cover-
age of five sequencing reads, a coverage we consider sufficient to 
confidently call DNA methylation levels for comparison to 450K 
arrays, e.g., in EWAS validation experiments (Fig. S4).
Finally, for FFPE samples, the fraction of target bases with a 
coverage of five sequencing reads was ~50%, suggesting impeded 
PCR amplification (Fig. S3C). We conclude that after bisulfite 
conversion of the already degraded DNA of the FFPE sample 
through the fixation and storage process, the DNA templates 
may be too short for microdroplet-based PCR amplification 
using a primer panel with an average PCR amplicon length of 
~200 bp (Fig. S1C). In future protocols, PCR amplification 
may be enhanced through the incorporation of locked nucleic 
acid (LNA) residues into primer sequences, which demonstrate 
increased affinity and specificity for very short DNA templates.21
Assessment of DNA methylation levels
We then extracted the methylation levels within the CpG con-
text, applying a cut-off of at least five sequencing reads covering 
the PCR amplicon (corresponding to a quantitative resolution of 
20%; Fig. S4). For the BM panel, we correlated the methylation 
levels at 497 and 1581 CpG sites across BL and SCL samples, 
respectively (Fig. 4A and B). Globally, we found that the meth-
ylation profiles were strongly correlated in unamplified samples 
(median R = 0.98). The strong correlation was confirmed (median 
R = 0.97) at 240, 774 and 13 CpG sites across BL, SCL and FFPE 
samples using the SC primer panel (Fig. S5A–C). These findings 
are in agreement with the notion that the fraction of target bases 
with a coverage of five sequencing reads is similar (see above and 
Fig. 3A and B).
Next, we correlated the methylation levels at CpG sites assessed 
with RainDrop BS-seq and 450K arrays in the same tissue type. 
For the BM panel, the correlation was R ≥ 0.91 for unamplified 
and R ≥ 0.79 for WGA samples in BL (n = 81 CpG sites) and 
SCL (n = 204 CpG sites), as shown in Figure 4A and B. These 
trends were again confirmed using the SC panel (Fig. S5A–C). 
We found that, particularly for unamplified samples, the correla-
tion was high across the entire quantitative range (Figs. S6A, 6B, 
and S7). DNA methylation scores showed a wide distribution 
across the assessed sites (Fig. 4C and D). CpGs in SCL samples 
were generally more methylated compared with BL samples.
For the BM panel, the CpG call rate was lower for the 10 
and 50 ng WGA samples (16.7–33.5%) compared with all other 
samples tested (46.5–53.0%). For these WGA samples in SCL 
but not BL, we observed a considerable deviation of median 
methylation levels compared with all other samples (Fig. 4D). 
Nonetheless, the methylation levels assessed at these CpG sites in 
BL and SCL samples correlated reasonably well with 450K arrays 
Figure 3. fraction of target bases with a coverage ranging from 1 to 1000 across target loci. the plots show the fraction of target bases with a coverage 
ranging from 1 to 1000 at 462 target loci across (A) BL and (B) SCL samples, assessed using the BM panel. Note that the x-axis is nonlinear. A coverage of 
five sequencing reads is indicated with a dotted line. With this coverage level, 80% of target bases were usually covered across all samples other than 
those with an input material of 10 and 50 ng. A reduction of the starting DNA amount resulted in decreased coverage overall at the target loci.
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(median R = 0.85). Thus, despite the reduced call rate for the 10 
and 50 ng WGA samples, we note that methylation levels can still 
be estimated. Finally, a graphical representation of the methyla-
tion profiles obtained using RainDrop BS-seq is shown in Figure 
S8, using the example of the LAMA2 and KCNQ1 target loci.
Conclusion
In this article, we assessed the recently introduced RainDrop 
BS-seq as a method for large-scale, targeted bisulfite sequencing. 
We demonstrated reliable microdroplet-based PCR amplifica-
tion of up to 500 target loci in human whole blood, an osteosar-
coma cell line and an FFPE sample. We showed that methylation 
profiles generated using a starting DNA amount of only 100 ng 
correlated well with 450K arrays. Further, we found that tiling 
of the genomic regions of choice using several overlapping PCR 
amplicons may improve target coverage. In our assessment, we 
did not find the application of MDA-based WGA to be benefi-
cial in conjunction with the RainDrop BS-seq workflow con-
cerning read coverage and CpG call rate, but presented good 
correlation of DNA methylation levels with those obtained on 
450K arrays. In conclusion, we suggest that RainDrop BS-seq 
may be applicable to large-scale EWAS validation and replication 
experiments, even when only nanogram quantities of DNA are 
available. As the sample throughput for EWAS increases (akin to 
those for genome-wide association studies; GWAS), novel tech-
niques such as RainDrop BS-seq are urgently needed to facilitate 
the experimental validation of the discovered association loci. 
Further studies (including one currently underway as part of 
the BLUEPRINT Consortium22) will address how the method 
presented here compares to other large-scale, targeted bisulfite 
sequencing methods.
Materials and Methods
Sample preparation
Genomic DNA was isolated from whole blood taken from 
a group of individuals using a GeneCatcher gDNA Blood Kit 
(Invitrogen) following the manufacturer’s protocol. Osteosarcoma 
143B cells were cultured and genomic DNA prepared as pre-
viously described.18 The preparation of genomic DNA from a 
FFPE tissue sample of a neuroendocrine tumor omental metas-
tasis (REC approval: 09/H0722/27) was described by Thirlwell 
et al.23 The DNA concentration was assessed using a Qubit 
dsDNA BR Assay Kit (Invitrogen).
Bisulfite conversion and WGA
Genomic DNA was bisulfite-treated using an EpiTect Bisulfite 
Kit (QIAGEN). We followed the standard protocol according 
Figure 4. Correlation of DNA methylation levels and comparison to 450K arrays. the heatmaps show matrices of pearson’s correlation coefficients across 
(A) BL samples (n = 497 CpG sites) and (B) SCL samples (n = 1581 CpG sites), assessed using the BM panel. the DNA methylation levels of unamplified 
samples with a starting DNA amount between 100 ng and 1500 ng were strongly correlated (median R = 0.98). further, we correlated a subset of these 
CpG sites, i.e., n = 81 and n = 204 CpGs across BL and SCL samples, that are represented on the 450K array. We found a strong correlation (R ≥ 0.91) for 
unamplified samples and a moderate correlation (R ≥ 0.79) for WGA samples. panels (C) and (D) show the distribution of DNA methylation scores at the 
assessed CpG sites.
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to the manufacturer’s instructions for BL and SCL samples, but 
used the optimized protocol for FFPE samples. For samples with 
a starting DNA material of less than 250 ng, we added Carrier 
RNA to BL Buffer. Purified bisulfite-converted DNA was eluted 
in 13 μl of EB Buffer. Selected samples were subjected to WGA 
using an EpiTect Whole Bisulfitome Kit (QIAGEN) following 
the manufacturer’s protocol. The entire sample of the bisulfite 
conversion reaction (~10 μl) was used for WGA.
Microdroplet PCR
For microdroplet PCR, 7.20 μl of bisulfite-treated (and 
optionally, whole-genome amplified) DNA were added to 4.70 
μl of 10× High-Fidelity Buffer (Invitrogen), 1.80 μl of 50 mM 
MgSO
4
 (Invitrogen), 1.62 μl of 10 mM dNTP solution mix 
(NEB), 3.60 μl of 4 M betaine solution (Sigma-Aldrich), 3.60 
μl of droplet stabilizer (RainDance Technologies), 1.80 μl of 
100% dimethyl sulfoxide (Sigma-Aldrich) and 0.72 μl of 5 U/μl 
Platinum Taq Polymerase High-Fidelity (Invitrogen), to a total 
volume of 25 μl. The sample plate was sealed using an ALPS 50V 
microplate heat sealer (Thermo Scientific).
The bisulfite-treated genomic DNA template mix was then 
applied to a fully automated ThunderStorm system (RainDance 
Technologies) following the manufacturer’s instructions. In 
brief, primer panel droplets (MethylSeq Solution, RainDance 
Technologies) were dispensed to a microfluidic chip. The DNA 
template mix was converted into droplets within the microfluidic 
chip. The primer pair droplets and template droplets were then 
paired together in a 1:1 ratio. Paired droplets passed through an 
electric field inducing the discrete droplets to coalesce into a sin-
gle PCR droplet (26 pl). Approximately 1 million PCR droplets 
are usually collected per sample.
PCR droplets were processed in a PTC-225 thermocycler (MJ 
Research) as follows: 94 °C for 2 min; 55 cycles of 94 °C for 
30 s, 54 °C for 45 s, 68 °C for 80 s; followed by 68 °C for 10 
min; 4 °C until further processing. The ramp rate was set to 1 
°C per second. Following PCR amplification, 70 μl of droplet 
destabilizer (RainDance Technologies) were added to each sam-
ple to break the PCR droplet emulsion and release the ampli-
cons contained within the droplets. The solution was mixed well 
and incubated for 15 min at RT. Samples were purified using 
Agencourt AMPure XP magnetic beads (Beckman Coulter) fol-
lowing the manufacturer’s protocol. For each sample, 234 μl of 
beads were used. Samples were eluted from magnetic beads in 
40 μl of EB Buffer. The integrity and concentration (fragment 
range: 120–250 bp) of purified amplicon DNA were assessed 
using a High Sensitivity DNA Kit (Agilent Technologies) on a 
2100 Bioanalyzer (Agilent Technologies).
Universal PCR
To prepare the samples for high-throughput DNA sequenc-
ing, Illumina adapter sequences and unique barcodes were intro-
duced through an additional PCR step. Here, 15 ng of purified 
amplicon DNA were added to 3.25 μl of 10x High-Fidelity 
Buffer, 0.88 μl of 50 mM MgSO
4
, 0.88 μl of 10 mM dNTP 
solution mix, 2.50 μl of 4 M betaine solution, 1.25 μl of 100% 
dimethyl sulfoxide, 0.50 μl of 5 U/μl Platinum Taq Polymerase 
High-Fidelity and 2.5 μl of 5 μM PCR primers, to a total volume 
of 25 μl. All primer sequences are provided in Table S3A.
Samples were amplified as follows: 94 °C for 2 min; 10 cycles 
of 94 °C for 30 s, 56 °C for 45 s, 68 °C for 60 s; followed by 
68 °C for 10 min; 4 °C until further processing. DNA was puri-
fied using a MinElute PCR Purification Kit (QIAGEN) accord-
ing to the manufacturer’s protocol. Purified DNA was eluted in 
10 μl of EB Buffer. Samples were quantified (fragment range: 
100–400 bp and 220–450 bp for the SC and BM panel, respec-
tively) using a DNA 1000 Kit on a 2100 Bioanalyzer. Of each 
sample, 50 ng were pooled. The resulting sequencing library was 
quantified using a Qubit dsDNA BR Assay Kit.
High-throughput DNA sequencing
The pooled sequencing library (12 pM) and custom sequenc-
ing primers (0.5 μM) were applied to a MiSeq 300-cycle PE 
consumable cartridge (Illumina) according to the manufacturer’s 
protocol. The DNA sequences of the custom sequencing prim-
ers are provided in Table S3B. Sequencing was performed on a 
MiSeq DNA sequencer (Illumina) using 75-bp paired-end reads.
Data and statistical analyses
Sequencing adapters were trimmed from the raw sequencing 
reads using the fastq-mcf tool of ea-utils v1.1.2-537 (parameter 
-k 0). Trimmed sequencing data were mapped to an in silico 
bisulfite-converted human reference genome (GRCh37) using 
Bismark v0.7.12 (parameters: -non_directional, -bowtie2).24 
Methylation information was extracted using the methylation_
extractor tool of Bismark v0.7.12 (parameters: -p, -comprehen-
sive, -merge_non_CpG). Targeted DNA sequencing analyses 
were performed using the R package TEQC v3.2.0.25 All statisti-
cal analyses were performed in R, an environment for statistical 
computing.
Methylation profiling on 450K arrays
Genomic DNA was prepared from whole blood and osteosar-
coma 143B cells as described above. Of each sample, 500 ng of 
gDNA were bisulfite-converted using an EZ DNA Methylation 
Kit (Zymo Research) following the manufacturer’s instructions, 
but using optimized incubation conditions (i.e., 16 cycles of 95 
°C for 30 s, 50 °C for 60 min; followed by 4 °C until further 
processing). Purified bisulfite-treated DNA was eluted in 15 μl 
of M-Elution Buffer. Array processing was performed following 
the Infinium HD Methylation Assay Guide (Illumina). Data 
analyses were performed using the R package ChAMP v1.0.6.26 
In brief, IDAT files were transformed into intensity (beta) values. 
We filtered probes with a median detection P value ≥ 0.01 in at 
least one sample. Beta values were normalized using the BMIQ 
(Beta Mixture Quantile dilation) method.27 By applying this 
method, the beta values of type II design probes were adjusted 
into a statistical distribution characteristic of type I probes.
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